Sjogren’s Syndrome Treatment Market Report and Forecast 2025-2034

Sjogren’s Syndrome Treatment Market Overview

Sjogren’s syndrome is a chronic autoimmune disease characterized by the immune system attacking the glands responsible for production of tears and saliva. This condition results in dry eye and dry mouth (also known as sicca symptoms). Nevertheless, it can also affect other body parts like lungs, kidneys, joints, and nerves etc. leading to wide range of symptoms and complications. The treatment for the syndrome includes symptomatic treatment, biologic agents, immune system suppression, and lifestyle adjustments. Nearly 4 % of the world’s population is affected by one of more than 80 different autoimmune diseases.

Sjogren’s Syndrome Treatment Market Growth Drivers

Increasing Research and Development Activities

To curb the burden of the autoimmune disease, the market is witnessing increased research and development of new drugs. There is an increasing involvement of organizations in conducting clinical trials to produce a treatment for the syndrome to help the patients with Sjogren’s syndrome. In November 2023, Amgen presented data from phase 2 trial of dazodalibep, a CD40 ligand antagonist in Sjögren's syndrome at American College of Rheumatology. The clinical trial was a randomized, double-blind, placebo-controlled crossover study evaluating two Sjögren's populations. The findings from the study demonstrated positive results that dazodalibep may improve both the systemic and symptomatic disease burden of people living with Sjögren's syndrome.

Growth in Strategic Partnerships and Mergers to Meet Rising Sjogren’s Syndrome Treatment Market Demand

In February 2024, PrecisionLife and Metrodora Institute collaborated to diagnose and treat complex chronic diseases including long COVID, ME/CFS, ALS, Sjögren's syndrome, and many more. Under the agreement, both partners aim to first develop and validate genotypic diagnostics to provide clinicians with an accurate view of patients’ risk of disease. This involves using molecular profiling to understand the underlying disease mechanisms. The insights are projected to help clinicians in making more informed prescribing decisions and identify new areas for drug discovery leading to improve patient outcomes.

Sjogren’s Syndrome Treatment Market Trends

Sjogren’s Syndrome Treatment Market Segmentation

Sjogren’s Syndrome Treatment Market Share

Market Segmentation Based on Drug Class is Projected to Experience Substantial Growth

Based on drug class, the market segmentation includes antimalarial quinolines, cholinergic agents, corticosteroids among others. Antimalarial quinolones are majorly used for their anti-inflammatory properties that caters to the systemic symptoms of the syndrome. This segment is predicted to observe steady growth because of its efficacy in reducing skin rash and fatigue associated with the syndrome. To address the chief symptoms of Sjogren’s syndrome such as dry eyes and mouth, cholinergic agents are used as they stimulate the secretion of saliva. The demand for cholinergic agents is estimated to grow as the number of diagnosed cases are increasing, thereby increasing the requirement of symptomatic relief.

Corticosteroids are incorporated into the treatment regimen to control severe symptoms involving vital organs like kidneys and lungs. These medications are crucial in managing inflammation. Their use is limited to a short span of time as it can cause long term side effects.

Targeted Drug Therapy Expected to Lead the Market Share

Based on therapy type, the market constitutes targeted drugs, pain relievers, symptom modulators, vaccines, surgery, and others. Targeted drugs such as B cell-depleting agents and inhibitors of B cell activation offer precision treatment by aiming on molecular targets associated with the syndrome. To curb the pain and ease the symptoms, the pain relivers and symptom modulators are expected to witness significant growth. This is also attributed to the widespread use of symptom modulators are the primary concern for Sjogren’s syndrome is to get relief from the symptoms of dry mouth and dry eye. Surgical interventions, though less common, are crucial for severe cases where glandular functionality is heavily compromised.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Sjogren’s Syndrome Treatment Market Analysis by Region

Regionally, the market report offers an insight into United States, EU-4 (including Spain, France, Italy and Germany) along with the United Kingdom, Japan and India. Leading the market with advanced healthcare infrastructure and investments in research and development, United States is projected to hold a significant market share in the forecast period. Increasing incidence of clinical trials in the region is also driving market growth in the region. Surge in investments in healthcare research and government support for innovations is boosting Europe’s Sjogren’s syndrome treatment market. The region also has a well-established infrastructure along with high awareness of autoimmune diseases.

Leading Players in the Sjogren’s Syndrome Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Denali Therapeutics

• Clovis Oncology

• Horizon Therapeutics Plc

• Sangamo Therapeutics

• AbbVie Inc.

• Advanz Pharma

• Biogen Inc.

• Bristol-Myers Squibb Company

• Daiichi Sankyo Company, Limited

• Hikma Pharmaceuticals PlC

• Johnson and Johnson

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in the Sjogren’s Syndrome Treatment Market Report

• What was the Sjogren’s syndrome treatment market value in 2023?
• What is the Sjogren’s syndrome treatment market forecast outlook for 2025-2034?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on drug class?
• What is the market breakup based on therapy type?
• Who are the major distribution channels in the market?
• What are the various route of administration in Sjogren’s syndrome treatment market?
• What are the major factors aiding the Sjogren’s syndrome treatment market demand? 
• How has the Sjogren’s syndrome treatment market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How does the prevalence and incidence of autoimmune diseases affect the market landscape?
• What are the major Sjogren’s Syndrome Treatment market trends?
• What drug class will dominate the market share? 
• Who are the key players involved in the Sjogren’s syndrome treatment market?
• What is patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

Sjogren’s Syndrome Treatment Market Report Snapshots

Sjogren’s Syndrome Treatment Market Size

Sjogren’s Syndrome Treatment Market Growth

Sjogren’s Syndrome Treatment Market Trends

Sjogren’s Syndrome Treatment Market Share

Sjogren’s Syndrome Treatment Market Regional Analysis

Sjogren’s Syndrome Treatment Companies